Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin and Metformin XR Initial Combination Therapy in T2DM
NCT01809327Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of canagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Janssen Pharmaceutical. Started Jun 2013; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01809327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01809327.